Table 1.
Study | Trial phase | Line of treatment | Underlying malignancy | Experimental drugs | PD-L1 antibody clone | Assay developer | IHC scoring method | Randomisation stratified by PD-L1 expression | No of patients | Median follow-up (months) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention | Control | |||||||||||||||
PD-L1 negative | PD-1 positive | PD-L1 negative | PD-1 positive | |||||||||||||
CheckMate 0178 9 | III | 2nd | Lung cancer | Nivolumab v docetaxel | 28-8 | Dako | Type I | No | 54 | 63 | 52 | 56 | >24 | |||
CheckMate 02510 | III | 2nd or later | Renal cancer | Nivolumab v everolimus | NR | Dako | Type I | No | 276 | 94 | 299 | 87 | 14 | |||
CheckMate 0578 11 | III | 2nd or later | Lung cancer | Nivolumab v docetaxel | 28-8 | Dako | Type I | No | 108 | 123 | 101 | 123 | >24 | |||
CheckMate 14112 | III | 2nd or later | Head and neck cancer | Nivolumab v chemotherapy | 28-8 | Dako | Type I | No | 73 | 88 | 38 | 61 | 5.1 | |||
KEYNOTE-00613 | III | 1st or 2nd | Melanoma | Pembrolizumab v ipilimumab | 22C3 | Merck | Type II | Yes | 103 | 446 | 47 | 225 | 22.9 | |||
KEYNOTE-04514 | III | 2nd or later | Urothelial cancer | Pembrolizumab v chemotherapy | 22C3 | Dako | Type II | No | NR* | NR† | NR* | NR† | 14.1 | |||
OAK15 | III | 2nd or later | Lung cancer | Atezolizumab v docetaxel | SP142 | VENTANA | Type II | Yes | 180 | 241 | 199 | 222 | 21 | |||
POPLAR16 | II | 2nd or later | Lung cancer | Atezolizumab v docetaxel | SP142 | VENTANA | Type II | Yes | 51 | 93 | 41 | 102 | 14.8 |
The total number of patients in the intervention and control groups is 298.
The total number of patients in the intervention and control groups is 230.
IHC=immunohistochemistry; Type I=membranous staining on tumour cells; Type II=membranous or cytoplasmic staining, or both, of tumour and immune cells; NR=not reported